CD274 and neoplasm: Pembrolizumab monotherapy is the current first-line standard-of-care therapy for patients with advanced or metastatic NSCLC tumors expressing programmed death-ligand 1 (PD-L1) and with no EGFR or ALK genomic tumor aberrations [3–6].